RPG Life Sciences Valuation

Is RPGLIFE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RPGLIFE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: RPGLIFE (₹1991.95) is trading above our estimate of fair value (₹825.67)

Significantly Below Fair Value: RPGLIFE is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RPGLIFE?

Key metric: As RPGLIFE is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for RPGLIFE. This is calculated by dividing RPGLIFE's market cap by their current earnings.
What is RPGLIFE's PE Ratio?
PE Ratio	46.6x
Earnings	₹706.60m
Market Cap	₹32.94b

RPGLIFE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	5.1x
Enterprise Value/EBITDA	22.2x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does RPGLIFE's PE Ratio compare to its peers?

The above table shows the PE ratio for RPGLIFE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	53.6x
506879 Gujarat Themis Biosyn	64.5x	n/a	₹34.0b
500288 Morepen Laboratories	30.9x	n/a	₹40.6b
INDOCO Indoco Remedies	92x	72.2%	₹29.5b
524348 Aarti Drugs	27.1x	31.5%	₹41.3b
RPGLIFE RPG Life Sciences	46.6x	n/a	₹32.9b

Price-To-Earnings vs Peers: RPGLIFE is good value based on its Price-To-Earnings Ratio (46.6x) compared to the peer average (53.6x).

Price to Earnings Ratio vs Industry

How does RPGLIFE's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 Companies	Price / Earnings	Estimated Growth	Market Cap
INDSWFTLAB Ind-Swift Laboratories	1.6x	n/a	US$70.43m
524652 Ind-Swift	2x	n/a	US$13.12m

No more companies available in this PE range

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: RPGLIFE is expensive based on its Price-To-Earnings Ratio (46.6x) compared to the Indian Pharmaceuticals industry average (31.7x).

Price to Earnings Ratio vs Fair Ratio

What is RPGLIFE's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RPGLIFE PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	46.6x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate RPGLIFE's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Caplin Point Laboratories

₹149.4b

Engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India.

CAPLIPOINT

₹1,963.75

0.6%

59.7%

Mercury Laboratories

₹1.1b

Develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally.

538964

₹928.00

-1.7%

15.6%

Solara Active Pharma Sciences

₹38.4b

Manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally.

541540

₹798.40

5.3%

137.7%